Literature DB >> 16474039

Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial.

L-S Tam, E K Li, C-K Wong, C W K Lam, W-C Li, C-C Szeto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16474039      PMCID： PMC1798050          DOI： 10.1136/ard.2005.044248

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  2 in total

1.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09
  2 in total
  10 in total

Review 1.  Effective treatment of Kimura's disease with leflunomide in combination with glucocorticoids.

Authors:  Lie Dai; Xiu-Ning Wei; Dong-Hui Zheng; Ying-Qian Mo; Frank Pessler; Bai-Yu Zhang
Journal:  Clin Rheumatol       Date:  2011-02-01       Impact factor: 2.980

2.  Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study.

Authors:  Yuan An; Yunshan Zhou; Liqi Bi; Bo Liu; Hong Wang; Jin Lin; Danyi Xu; Mei Wang; Jing Zhang; Yongfu Wang; Yan An; Ping Zhu; Ronghua Xie; Zhiyi Zhang; Yifang Mei; Xiangyuan Liu; Xiaoli Deng; Zhongqiang Yao; Zhuoli Zhang; Yu Wang; Weiguo Xiao; Hui Shen; Xiuyan Yang; Hanshi Xu; Feng Yu; Guochun Wang; Xin Lu; Yang Li; Yingnan Li; Xiaoxia Zuo; Yisha Li; Yi Liu; Yi Zhao; Jianping Guo; Lingyun Sun; Minghui Zhao; Zhanguo Li
Journal:  Clin Rheumatol       Date:  2018-11-28       Impact factor: 2.980

3.  4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.

Authors:  Onkar P Kulkarni; Sufyan G Sayyed; Claudia Kantner; Mi Ryu; Max Schnurr; Miklós Sárdy; Johann Leban; Ruediger Jankowsky; Aldo Ammendola; Robert Doblhofer; Hans-Joachim Anders
Journal:  Am J Pathol       Date:  2010-04-22       Impact factor: 4.307

4.  Expert Perspective: An Approach to Refractory Lupus Nephritis.

Authors:  Swati Arora; Brad H Rovin
Journal:  Arthritis Rheumatol       Date:  2022-04-25       Impact factor: 15.483

Review 5.  Leflunomide: friend or foe for systemic lupus erythematosus?

Authors:  Guo-Cui Wu; Xiao-Di Xu; Qiong Huang; Hua Wu
Journal:  Rheumatol Int       Date:  2012-09-08       Impact factor: 2.631

6.  Pseudo-pseudo Meigs syndrome developed under the leflunomide therapy.

Authors:  Cemal Bes; Mehmet Soy
Journal:  Rheumatol Int       Date:  2009-10-21       Impact factor: 2.631

7.  Integrated, multicohort analysis reveals unified signature of systemic lupus erythematosus.

Authors:  Winston A Haynes; D James Haddon; Vivian K Diep; Avani Khatri; Erika Bongen; Gloria Yiu; Imelda Balboni; Christopher R Bolen; Rong Mao; Paul J Utz; Purvesh Khatri
Journal:  JCI Insight       Date:  2020-02-27

Review 8.  Current status of lupus nephritis.

Authors:  Ajay Jaryal; Sanjay Vikrant
Journal:  Indian J Med Res       Date:  2017-02       Impact factor: 2.375

9.  Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.

Authors:  George K Bertsias; Maria Tektonidou; Zahir Amoura; Martin Aringer; Ingeborg Bajema; Jo H M Berden; John Boletis; Ricard Cervera; Thomas Dörner; Andrea Doria; Franco Ferrario; Jürgen Floege; Frederic A Houssiau; John P A Ioannidis; David A Isenberg; Cees G M Kallenberg; Liz Lightstone; Stephen D Marks; Alberto Martini; Gabriela Moroni; Irmgard Neumann; Manuel Praga; Matthias Schneider; Argyre Starra; Vladimir Tesar; Carlos Vasconcelos; Ronald F van Vollenhoven; Helena Zakharova; Marion Haubitz; Caroline Gordon; David Jayne; Dimitrios T Boumpas
Journal:  Ann Rheum Dis       Date:  2012-07-31       Impact factor: 19.103

10.  The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study.

Authors:  Andreas Muehler; Hella Kohlhof; Manfred Groeppel; Daniel Vitt
Journal:  Drugs R D       Date:  2019-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.